Efficacy of granisetron, a 5-HT3 antagonist, in the prevention of nausea and vomiting induced by conditioning for hematopoietic stem cell transplantation

N. Hirabayashi, S. Goto, Y. Morishima, H. Sao, T. Matsuyama, Y. Kodera, H. Yamada, K. Horibe, K. Yano, H. Kojima, M. Ogura, M. Tanimoto, Y. Morishita, M. Yazaki, M. Utsumi, K. Nagata, Y. Kato, T. Naoe, H. Saito

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

One hundred and eleven patients receiving conditioning regimens for hematopoietic stem cell transplantation (HSCT) were administered a single intravenous dose (40 micrograms/kg) of granisetron before chemo-radio therapy. The efficacy of the drug was assessed every 24 hours, rating the control of nausea and vomiting as complete, major, minor or failure. On day 1, 23 of 48 patients (47.9%) who received cyclophosphamide (60 mg/kg/day), achieved control of emesis with complete or major response. On day 2, 17 of 47 patients (36.2%) achieved control emesis. During total body irradiation (TBI) (10 approximately 12 Gy/2 approximately 3 days), 21 of 33 patients (63.6%) achieved control of emesis on day 1 and 22 of 32 patients (68.6%) achieved control of emesis on day 2. During melphalan administration (60 approximately 100 mg/m2/day), 20 of 28 patients (71.4%) achieved control of emesis on day 1. Adverse effects were observed in seven patients but were not serious. We concluded that granisetron has a major role in preparation for HSCT.

Original languageEnglish
Pages (from-to)21-26
Number of pages6
Journal[Rinshō ketsueki] The Japanese journal of clinical hematology
Volume39
Issue number1
Publication statusPublished - 1998
Externally publishedYes

Fingerprint

Granisetron
Serotonin 5-HT3 Receptor Antagonists
Hematopoietic Stem Cell Transplantation
Nausea
Vomiting
Melphalan
Whole-Body Irradiation
Radio
Cyclophosphamide

Cite this

Efficacy of granisetron, a 5-HT3 antagonist, in the prevention of nausea and vomiting induced by conditioning for hematopoietic stem cell transplantation. / Hirabayashi, N.; Goto, S.; Morishima, Y.; Sao, H.; Matsuyama, T.; Kodera, Y.; Yamada, H.; Horibe, K.; Yano, K.; Kojima, H.; Ogura, M.; Tanimoto, M.; Morishita, Y.; Yazaki, M.; Utsumi, M.; Nagata, K.; Kato, Y.; Naoe, T.; Saito, H.

In: [Rinshō ketsueki] The Japanese journal of clinical hematology, Vol. 39, No. 1, 1998, p. 21-26.

Research output: Contribution to journalArticle

Hirabayashi, N, Goto, S, Morishima, Y, Sao, H, Matsuyama, T, Kodera, Y, Yamada, H, Horibe, K, Yano, K, Kojima, H, Ogura, M, Tanimoto, M, Morishita, Y, Yazaki, M, Utsumi, M, Nagata, K, Kato, Y, Naoe, T & Saito, H 1998, 'Efficacy of granisetron, a 5-HT3 antagonist, in the prevention of nausea and vomiting induced by conditioning for hematopoietic stem cell transplantation', [Rinshō ketsueki] The Japanese journal of clinical hematology, vol. 39, no. 1, pp. 21-26.
Hirabayashi, N. ; Goto, S. ; Morishima, Y. ; Sao, H. ; Matsuyama, T. ; Kodera, Y. ; Yamada, H. ; Horibe, K. ; Yano, K. ; Kojima, H. ; Ogura, M. ; Tanimoto, M. ; Morishita, Y. ; Yazaki, M. ; Utsumi, M. ; Nagata, K. ; Kato, Y. ; Naoe, T. ; Saito, H. / Efficacy of granisetron, a 5-HT3 antagonist, in the prevention of nausea and vomiting induced by conditioning for hematopoietic stem cell transplantation. In: [Rinshō ketsueki] The Japanese journal of clinical hematology. 1998 ; Vol. 39, No. 1. pp. 21-26.
@article{29c5a283a23f4742b27e43ae38d85066,
title = "Efficacy of granisetron, a 5-HT3 antagonist, in the prevention of nausea and vomiting induced by conditioning for hematopoietic stem cell transplantation",
abstract = "One hundred and eleven patients receiving conditioning regimens for hematopoietic stem cell transplantation (HSCT) were administered a single intravenous dose (40 micrograms/kg) of granisetron before chemo-radio therapy. The efficacy of the drug was assessed every 24 hours, rating the control of nausea and vomiting as complete, major, minor or failure. On day 1, 23 of 48 patients (47.9{\%}) who received cyclophosphamide (60 mg/kg/day), achieved control of emesis with complete or major response. On day 2, 17 of 47 patients (36.2{\%}) achieved control emesis. During total body irradiation (TBI) (10 approximately 12 Gy/2 approximately 3 days), 21 of 33 patients (63.6{\%}) achieved control of emesis on day 1 and 22 of 32 patients (68.6{\%}) achieved control of emesis on day 2. During melphalan administration (60 approximately 100 mg/m2/day), 20 of 28 patients (71.4{\%}) achieved control of emesis on day 1. Adverse effects were observed in seven patients but were not serious. We concluded that granisetron has a major role in preparation for HSCT.",
author = "N. Hirabayashi and S. Goto and Y. Morishima and H. Sao and T. Matsuyama and Y. Kodera and H. Yamada and K. Horibe and K. Yano and H. Kojima and M. Ogura and M. Tanimoto and Y. Morishita and M. Yazaki and M. Utsumi and K. Nagata and Y. Kato and T. Naoe and H. Saito",
year = "1998",
language = "English",
volume = "39",
pages = "21--26",
journal = "[Rinsho ketsueki] The Japanese journal of clinical hematology",
issn = "0485-1439",
publisher = "Nihon Rinsho Ketsueki Gakkai/Japan Society of Clinical Hematology",
number = "1",

}

TY - JOUR

T1 - Efficacy of granisetron, a 5-HT3 antagonist, in the prevention of nausea and vomiting induced by conditioning for hematopoietic stem cell transplantation

AU - Hirabayashi, N.

AU - Goto, S.

AU - Morishima, Y.

AU - Sao, H.

AU - Matsuyama, T.

AU - Kodera, Y.

AU - Yamada, H.

AU - Horibe, K.

AU - Yano, K.

AU - Kojima, H.

AU - Ogura, M.

AU - Tanimoto, M.

AU - Morishita, Y.

AU - Yazaki, M.

AU - Utsumi, M.

AU - Nagata, K.

AU - Kato, Y.

AU - Naoe, T.

AU - Saito, H.

PY - 1998

Y1 - 1998

N2 - One hundred and eleven patients receiving conditioning regimens for hematopoietic stem cell transplantation (HSCT) were administered a single intravenous dose (40 micrograms/kg) of granisetron before chemo-radio therapy. The efficacy of the drug was assessed every 24 hours, rating the control of nausea and vomiting as complete, major, minor or failure. On day 1, 23 of 48 patients (47.9%) who received cyclophosphamide (60 mg/kg/day), achieved control of emesis with complete or major response. On day 2, 17 of 47 patients (36.2%) achieved control emesis. During total body irradiation (TBI) (10 approximately 12 Gy/2 approximately 3 days), 21 of 33 patients (63.6%) achieved control of emesis on day 1 and 22 of 32 patients (68.6%) achieved control of emesis on day 2. During melphalan administration (60 approximately 100 mg/m2/day), 20 of 28 patients (71.4%) achieved control of emesis on day 1. Adverse effects were observed in seven patients but were not serious. We concluded that granisetron has a major role in preparation for HSCT.

AB - One hundred and eleven patients receiving conditioning regimens for hematopoietic stem cell transplantation (HSCT) were administered a single intravenous dose (40 micrograms/kg) of granisetron before chemo-radio therapy. The efficacy of the drug was assessed every 24 hours, rating the control of nausea and vomiting as complete, major, minor or failure. On day 1, 23 of 48 patients (47.9%) who received cyclophosphamide (60 mg/kg/day), achieved control of emesis with complete or major response. On day 2, 17 of 47 patients (36.2%) achieved control emesis. During total body irradiation (TBI) (10 approximately 12 Gy/2 approximately 3 days), 21 of 33 patients (63.6%) achieved control of emesis on day 1 and 22 of 32 patients (68.6%) achieved control of emesis on day 2. During melphalan administration (60 approximately 100 mg/m2/day), 20 of 28 patients (71.4%) achieved control of emesis on day 1. Adverse effects were observed in seven patients but were not serious. We concluded that granisetron has a major role in preparation for HSCT.

UR - http://www.scopus.com/inward/record.url?scp=0031601731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031601731&partnerID=8YFLogxK

M3 - Article

VL - 39

SP - 21

EP - 26

JO - [Rinsho ketsueki] The Japanese journal of clinical hematology

JF - [Rinsho ketsueki] The Japanese journal of clinical hematology

SN - 0485-1439

IS - 1

ER -